lipogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
RNAi Atlas: a database of RNAi libraries and their target analysis results miRSearch Archived 2012-12-04 at the Wayback Machine: Tool for finding microRNAs that target mRNA How mRNA is coded?: YouTube video What is mRNA?: theconversation.com
==== International Baccalaureate ==== The International Baccalaureate (IB) Diploma Magnet Program is a course of study. The mission of the program is to develop inquiring, knowledgeable, and caring young people who help to create a better, more peaceful world through intercultural understanding and respect. The IB program offers many benefits to its participants, such as: higher university and college acceptance rates for IB graduates; increased scholarship and grant opportunities; a college-level academic program that transitions students to university and college standards; and teacher development using IB strategies. Locations:
== Transcendental/reverse dependent origination == Understanding dependent origination is indispensable for realizing nirvana since it leads to insight into how the process of dependent arising can be brought to an end (i.e. nirvana). Since the process of dependent origination always produces suffering, the reversal or deactivation of the sequence is seen by Buddhists as the way to stop the entire process. Traditionally, the reversal of the sequence of the twelve nidanas is explained as leading to the cessation of rebirth and suffering. The early Buddhist texts state that on the arising of wisdom or insight into the true nature of things, dependent origination ceases. Some suttas state that "from the fading and cessation of ignorance without remainder comes the cessation of saṅkhāras..." et cetera (this is said to lead to the cessation of the entire twelve-fold chain in reverse order). According to Jayarava Attwood, while some dependent origination passages (termed lokiya, worldly) "[model] beings trapped in cycles of craving and grasping, birth and death", other passages (termed lokuttara, 'beyond the world') "[model] the process and dynamics of liberation from those same cycles." According to Bodhi, these are also classified as "exposition of the round" (vaṭṭakathā) and "the ending of the round" (vivaṭṭakathā). Beni Barua called these two different kinds of dependent origination "cyclic" and "progressive".
=== 3: Primary Active Transporters === 3.A: P-P-bond-hydrolysis-driven transporters (a.k.a. ATP-driven pumps, or transport ATPases): ATP-binding cassette transporter (ABC transporter), such as MDR, CFTR V-type ATPase; ( "V" related to vacuolar ). P-type ATPase; ( "P" related to phosphorylation), such as: Na+/K+-ATPase Plasma membrane Ca2+ ATPase Proton pump F-type ATPase; ("F" related to factor), including: mitochondrial ATP synthase, chloroplast ATP synthase1 3.B: Decarboxylation-driven transporters 3.C: Methyltransfer-driven transporters 3.D: Oxidoreduction-driven transporters 3.E: Light absorption-driven transporters, such as rhodopsin
Risk of developing CJD increases with age. CJD incidence was 3.5 cases per million among those over 50 years of age between 1979 and 2017. Approximately 85% of CJD cases are sporadic, and 10–15% of CJD cases are due to inherited mutations of the prion protein gene. CJD deaths and age-adjusted death rate in the United States indicate an increasing trend in the number of deaths between 1979 and 2017. Although not fully understood, additional information suggests that CJD rates in nonwhite groups are lower than in whites. While the mean onset is approximately 67 years of age, cases of sCJD have been reported as young as 17 years and over 80 years of age. Mental capabilities rapidly deteriorate and the average amount of time from onset of symptoms to death is 7 to 9 months. According to a 2020 systematic review on the international epidemiology of CJD:
Sources: en.wikipedia.org
Tbr1, along with Pax6 and Tbr2, has a role in glutamatergic projection neuron differentiation. Glutamatergic neurons make and release in an activity-dependent manner the excitatory neurotransmitter glutamate as opposed to the inhibitory neurotransmitter GABA. The transition from radial glial cells to postmitotic projection neurons occurs in three steps, each associated with one of the aforementioned transcription factors. The first starts out with the expression of Pax6 in radial glial cells found primarily at the ventricular surface. In the next step, Pax6 is downregulated and Tbr2 is expressed as the cell differentiates into an intermediate progenitor cell. Likewise, in the final step, Tbr2 is extremely downregulated to undetectable levels as Tbr1 signals the transition into a postmitotic projection neuron.
=== Fission product === In contrast to the rare natural occurrence, bulk quantities of technetium-99 are produced each year from spent nuclear fuel rods, which contain various fission products. The fission of a gram of uranium-235 in nuclear reactors yields 27 mg of technetium-99, giving technetium a fission product yield of 6.1%. Other fissile isotopes produce similar yields of technetium, such as 4.9% from uranium-233 and 6.21% from plutonium-239. An estimated 49,000 TBq (78 metric tons) of technetium was produced in nuclear reactors between 1983 and 1994, by far the dominant source of terrestrial technetium. Only a fraction of the production is used commercially. Technetium-99 is produced by the nuclear fission of both uranium-235 and plutonium-239. It is therefore present in radioactive waste and in the nuclear fallout of fission bomb explosions. Its decay, measured in becquerels per amount of spent fuel, is the dominant contributor to nuclear waste radioactivity after about 104–106 years after the creation of the nuclear waste. From 1945 to 1994, an estimated 160 TBq (about 250 kg) of technetium-99 was released into the environment during atmospheric nuclear tests. The amount of technetium-99 from nuclear reactors released into the environment up to 1986 is on the order of 1000 TBq (about 1600 kg), primarily by nuclear fuel reprocessing; most of this was discharged into the sea.
=== Type 2 diabetes === In the BEGIN Basal-Bolus Type 2 trial, insulin degludec was studied as an alternative to insulin glargine in participants with type 2 diabetes. 995 participants were randomized to receive either insulin degludec (n=755) or insulin glargine (n=251), in addition to either mealtime insulin aspart, metformin, and/or pioglitazone. Participants in this trial had an average HbA1c of 8.3–8.4%, and 49–50% were on a regimen consisting of basal-bolus insulin plus oral antidiabetic medications. After 52 weeks, insulin degludec was found to be noninferior to insulin glargine, providing a similar HbA1c lowering effect (−1.10 vs. −1.18%). Overall rates of hypoglycemia were significantly lower with insulin degludec (11.09 vs. 13.63%/yr, p=0.0359), including cases of nocturnal hypoglycemia (1.39 vs. 1.84%/yr, p=0.0399).
== External links == Kavkaz-2008 leaflet ("Soldier, know your probable enemy"), The Guns of August 2008: Russia's War in Georgia, p. xi - xii Anna Nemtsova, Q&A: Georgia's Mikheil Saakashvili on Russia Fight, Newsweek, 11 August 2008 William Rees-Mogg, Georgia: another Sarajevo moment avoided, The Times, 11 August 2008 Illarionov: Russia Lost the Georgian War, The Other Russia, 13 August 2008 (in Russian) "We Will never surrender", Der Spiegel, 18 August 2008 (in Russian) Vadim Rechakolv's comment on the movement of Russian tank column through the Roki Tunnel on 7 August Denis Macshane, Denis MacShane Explores the Myths About Russia, Newsweek, 5 September 2008 Ministry of Foreign Affairs of Georgia, Media and telephone intercepts confirm Russia started the war, 20 September 2008 (in Russian) André Glucksmann, Putin's doctrine, 22 October 2008 The Government of Georgia, Factual Evidence Contradicts War Claims in Recent Media Stories;, 18 November 2008 Bear on the Prowl? The Return of Russia as a Great Power Archived 17 March 2024 at the Wayback Machine; Australian Institute of International Affairs, November 2008 Julia Latynina - Articles on August war (Translations) Report by the Government of Georgia on the aggression by the Russian Federation against Georgia, 7 August 2009. PDF file. (in Russian) Grani TV, Andrei Nekrasov, Movie director, Garry Kasparov about "Russian Lessons", 14 September 2009 Caucasus Analytical Digest No.
== Treatment == If nipple pain is not resolved effectively after general management, appropriate treatment can be directed at underlying causes. Nevertheless, except the general management mentioned before, all common therapeutic practices in treating nipple pain during breastfeeding are not proven to be effective yet.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.